Oppilotech
Private Company
Funding information not available
Overview
Oppilotech is a private, early-stage biotech firm utilizing a proprietary AI/ML-driven computational platform for systems biology modeling to enhance drug target selection and discovery. Founded in London in 2020 by a team with pharma, biotech, and academic experience, the company operates as both a platform developer and a therapeutic program creator. It is currently pre-revenue and pre-clinical, offering modeling services while building its own pipeline of first-in-class drugs. The company's strategy focuses on de-risking early-stage R&D by providing novel biological insights to internal programs and potential partners.
Technology Platform
A predictive computational modeling platform integrating systems biology and machine learning to simulate biological processes and identify novel drug targets.
Opportunities
Risk Factors
Competitive Landscape
Competes with numerous other AI/ML-driven drug discovery companies (e.g., Recursion, Exscientia, Insilico Medicine) and computational biology firms. Differentiation hinges on the unique architecture of its systems biology and ML integration and its ability to generate proprietary, actionable insights.